Clinical and histological evolution after de novo donor-specific anti-human leukocyte antigen antibodies: a single centre retrospective study

Bouatou, Yassine; Seyde, Olivia; Moll, Solange; Martin, Pierre-Yves; Villard, Jean; Ferrari-Lacraz, Sylvie; Hadaya, Karine

doi:10.1186/s12882-018-0886-5

Scientific article

English

Clinical and histological evolution after de novo donor-specific anti-human leukocyte antigen antibodies: a single centre retrospective study

ContributorsBouatou, Yassine; Seyde, Olivia; Moll, Solange; Martin, Pierre-Yves; Villard, Jean; Ferrari-Lacraz, Sylvie; Hadaya, Karine

Published inBMC Nephrology, vol. 19, no. 1, 86

Publication date2018

Abstract

Donor-specific anti-human leukocyte antigen (HLA) antibodies (DSA) can be preformed or de novo (dn). Strategies to manage preformed DSA are well described, but data on the management and outcomes of dnDSA are lacking.

Affiliation entities

Research groups

Citation (ISO format)

BOUATOU, Yassine et al. Clinical and histological evolution after de novo donor-specific anti-human leukocyte antigen antibodies: a single centre retrospective study. In: BMC Nephrology, 2018, vol. 19, n° 1, p. 86. doi: 10.1186/s12882-018-0886-5

Article (Published version)

CC BY

Identifiers

PID : unige:105765
DOI : 10.1186/s12882-018-0886-5
PMID : 29649973

Journal ISSN1471-2369

556views

217downloads

Creation07/06/2018 14:50:00

First validation07/06/2018 14:50:00

Update14/11/2024 14:52:31

Status update14/11/2024 14:52:31

Last indexation14/11/2024 14:56:20

Archive ouverte UNIGE

Clinical and histological evolution after de novo donor-specific anti-human leukocyte antigen antibodies: a single centre retrospective study

Donor-specific anti-human leukocyte antigen (HLA) antibodies (DSA) can be preformed or de novo (dn). Strategies to manage preformed DSA are well described, but data on the management and outcomes of dnDSA are lacking.

Technical informations